Lords Mark Industries Gets MHRA Registration for IVD Portfolio

Lords Mark Industries Limited has received MHRA registration for its In-Vitro Diagnostics (IVD) portfolio, including haematological cell analysers and clinical chemistry analysers. This registration, dated September 24, 2026, allows the company to commence commercial sales of its IVD products in the UK from December 2026, ahead of its earlier schedule. This follows a recent MHRA registration for their AI-powered haemodialysis system. The company plans to leverage the UK market as a platform for expansion into UK-allied countries and is integrating its IVD products with advanced medical technology and diagnostic services. Furthermore, Lords Mark Industries plans to launch a pathology laboratory in January 2027, aiming for an integrated healthcare strategy in the region.